CSIMarket Company Name, Ticker, Suppliers, else..
 
Enliven Therapeutics Inc   (NASDAQ: ELVN)
Other Ticker:  
 
 
Price: $21.8600 $-0.18 -0.817%
Day's High: $22.3675 Week Perf: 1.82 %
Day's Low: $ 21.64 30 Day Perf: -2.71 %
Volume (M): 510 52 Wk High: $ 30.03
Volume (M$): $ 11,144 52 Wk Avg: $22.03
Open: $21.98 52 Wk Low: $10.90



 Market Capitalization (Millions $) 1,055
 Shares Outstanding (Millions) 48
 Employees 19
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -85
 Cash Flow (TTM) (Millions $) 27
 Capital Exp. (TTM) (Millions $) 0

Enliven Therapeutics Inc
Enliven Therapeutics Inc is a pharmaceutical company that focuses on developing innovative therapies for a variety of diseases and conditions. The company employs cutting-edge technologies and research methods to discover, design, and develop new medications. Enliven Therapeutics Inc aims to improve patient outcomes and quality of life by addressing unmet medical needs. Their team of scientists, researchers, and medical professionals work diligently to create safe and effective treatments that can positively impact the lives of patients.


   Company Address: 6200 Lookout Road Boulder 80301 CO
   Company Phone Number: 647-8519   Stock Exchange / Ticker: NASDAQ ELVN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD      % 
BMY      % 
REGN      % 
SUPN      % 
UTHR      % 
VRTX      % 
• View Complete Report
   



Clinical Study

Navigating Promising Clinical Trials Amid Financial Challenges A Close Look at Enliven Therapeutics

Published Sat, Sep 28 2024 1:35 PM UTC

Enliven Therapeutics has garnered attention in the biopharmaceutical landscape with the recent announcement of positive updates from its Phase 1 clinical trial for ELVN-001, a promising therapeutic candidate aimed at treating Chronic Myeloid Leukemia (CML). This information was presented at the 26th Annual John Goldman Conference, ESH-iCMLf, showcasing the potential efficacy...
Clinical Study

Enliven Therapeutics Unveils Promising Phase 1 Trial Results for Leukemia Treatment and Announces $90M Investment

Published Thu, Apr 11 2024 11:55 AM UTC

Enliven Therapeutics, a leading drug discovery and development company, has recently announced heartening results from the novel Phase 1 clinical trial of their revolutionary drug ELVN-001, targeted at combating Chronic Myeloid Leukemia (CML). This significant milestone coincides with their disclosure of a $90 million private placement financing, bolstering the company s rob...
Clinical Study

Enliven Therapeutics Unveils Revolutionary Cancer Drug ELVN-001: Initial Proof of Concept Data Revealed in Virtual Key Opinion Leader Event

Published Thu, Mar 28 2024 8:05 PM UTC

Enliven Therapeutics Presents Exciting Data on Revolutionary Cancer Drug ELVN-001 in Virtual Key Opinion Leader EventBOULDER, Colo., March 28, 2024 - Enliven Therapeutics, Inc. (Nasdaq: ELVN), a leading clinical-stage precision oncology company pioneering the development of next-generation small molecule kinase inhibitors, is thrilled to announce the highly anticipated webca...
Clinical Study

Enliven Therapeutics' $90 Million Private Placement Financing Unlocks Promising Potential for Pipeline Advancements

Published Tue, Mar 19 2024 12:30 PM UTC

In recent news, Enliven Therapeutics has made significant strides towards advancing their innovative therapeutic treatments with the announcement of a successful $90 million private placement financing. This substantial investment highlights the confidence both new and existing investors have in the company s potential, paving the way for groundbreaking advancements in the f...
Enliven Therapeutics Inc

Restructuring Challenges Major Pharmaceutical Preparations Company, Leading to Operating Struggles in Fiscal Third Quarter of 20232.

Enliven Therapeutics Inc, a smaller corporation in the Major Pharmaceutical Preparations industry, recently reported a significant operating shortfall of $-24.248 million for the third quarter of 2023. This news has caused concerns among investors who were hoping for new revenue streams to emerge soon. However, the market seems less interested in the company's current proficiency in the industry.
In their pursuit of establishing lucrative revenue streams, companies often go through challenging periods. One such instance was the fiscal interval ending on September 30, 2023, where the shortfalls expanded to $-20.769 million. This suggests that Enliven Therapeutics Inc may be facing difficulties in generating sufficient profits and sustaining growth.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com